Publications and presentations
Nonoperative Management of Mismatch Repair–Deficient Tumors
Cercek et al. | April 2025 | Publication
Haystack MRD was used in a groundbreaking study in the New England Journal of Medicine showing that in many patients with early-stage mismatch repair-deficient (dMMR) solid tumors, immunotherapy could prevent the need for surgery, chemotherapy, and radiation. In the study, Haystack MRD identified clinical complete response in as little as 1.4 months.
Two leading oncologists take a deep dive into how groundbreaking advancements are providing a clearer crystal ball for guiding patient care
Flora & Patt | October 2024 | Video
Budget Impact Analysis of Circulating Tumor DNA Testing for Colon Cancer in Commercial Health and Medicare Advantage Plans
Li et al. | May 2024 | Publication
Circulating tumor DNA (ctDNA) testing for minimal residual disease (MRD) can reduce costs by up to 21% across health plan populations when half of eligible patients with stage II colorectal cancer are tested for treatment decisions.
Applying precision technology to improve the detection of residual disease in cancer patients
Haystack Oncology | March 2023 | Article
Clinicians’ Perspectives on Circulating Tumor DNA MRD Testing in Personalizing Adjuvant Therapy for Stage II Colon Cancer
Barzi & Tie | August 2022 | Webinar
Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
Tie et al | June 2022 | Publication
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of 3 cohort studies
Tie et al | 2021 | Publication
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study
Tie et al | 2019 | Publication
Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer
Tie et al | 2019 | Publication
Prognostic Potential of Circulating Tumor DNA Measurement in Postoperative Surveillance of Nonmetastatic Colorectal Cancer
Wang et al | 2019 | Publication
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
Tie et al | July 2016 | Publication
Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer
Tie et al | 2015 | Publication
Detection of circulating tumor DNA in early- and late-stage human malignancies
Bettegowda et al | 2014 | Publication
Detection and quantification of rare mutations with massively parallel sequencing
Kinde et al | May 2011 | Publication
Circulating mutant DNA to assess tumor dynamics
Diehl et al | July 2008 | Publication
First clinical evidence for circulating tumor DNA (ctDNA)-based liquid biopsy as a method to reliably monitor disease status in cancer patients. First application and clinical evidence demonstrating utility of postsurgical tumor-informed MRD testing.